Norton J A, Doppman J L, Collen M J, Harmon J W, Maton P N, Gardner J D, Jensen R T
Ann Surg. 1986 Oct;204(4):468-79. doi: 10.1097/00000658-198610000-00015.
In 1982, a prospective study was initiated of 52 consecutive patients with proven Zollinger-Ellison syndrome (ZES), involving surgical exploration with the goal of removing the gastrinoma after an extensive protocol to localize the tumor. Each patient underwent ultrasound, computed tomography (CT) with oral/intravenous (IV) contrast, and selective arteriography. Eighteen patients had metastatic disease identified by imaging studies and confirmed by percutaneous biopsies, and two patients had multiple endocrine neoplasia type I (MEN-I) with negative imaging studies; therefore, these 20 patients did not undergo laparotomy. Each of the remaining 32 patients (3 with MEN-I and positive imaging studies) underwent laparotomy, and gastrinomas were removed in 20 patients. Preoperative ultrasound localized tumors in 20% of patients, CT in 40%, arteriography in 60%, and any of the modalities in 70% of patients. Infusion CT and arteriography were 100% specific. In 18 patients with either negative imaging (17) or false-positive imaging (1 ultrasound), gastrinomas were found and removed in six patients (33%). Twenty-four gastrinomas were found in 20 patients at laparotomy: eight in lymph nodes around the pancreatic head, four in the pancreatic head, one in the pancreatic body, three in the pancreatic tail, three in the pyloric channel, one in the duodenal wall, two in the jejunum at the ligament of Treitz, one in the ovary, and multiple liver metastases in one patient. If one excludes patients with MEN-I or liver metastatic disease, 12/28 (43%) of patients were biochemically "cured" immediately after operation. This result decreased to 7/23 (30%) with greater than 6 months follow-up. No patients with gastrinomas resected have developed recurrent gastrinoma on follow-up imaging studies (longest follow-up: 4 years). This study indicates that 95% of metastatic gastrinoma can be diagnosed before operation and that, by a combination of careful imaging studies and thorough exploration at surgery, 30% of patients with gastrinomas may be curable.
1982年,一项前瞻性研究纳入了52例经证实患有卓-艾综合征(ZES)的连续患者,该研究在实施广泛的肿瘤定位方案后,以手术探查并切除胃泌素瘤为目标。每位患者均接受了超声、口服/静脉注射(IV)造影剂的计算机断层扫描(CT)以及选择性动脉造影。18例患者经影像学检查发现有转移性疾病,并经经皮活检证实,2例患者患有I型多发性内分泌腺瘤病(MEN-I)但影像学检查结果为阴性;因此,这20例患者未接受剖腹手术。其余32例患者(3例患有MEN-I且影像学检查结果为阳性)均接受了剖腹手术,其中20例患者的胃泌素瘤被切除。术前超声定位出肿瘤的患者占20%,CT占40%,动脉造影占60%,任何一种检查方式定位出肿瘤的患者占70%。增强CT和动脉造影的特异性均为100%。在18例影像学检查结果为阴性(17例)或假阳性(1例超声检查)的患者中,6例患者(33%)发现并切除了胃泌素瘤。剖腹手术中,20例患者共发现24个胃泌素瘤:胰头周围淋巴结8个,胰头4个,胰体1个,胰尾3个,幽门管3个,十二指肠壁1个,Treitz韧带处空肠2个,卵巢1个,1例患者有多发肝转移。如果排除患有MEN-I或肝转移性疾病的患者,12/28(43%)的患者术后立即实现了生化“治愈”。随访6个月以上时,这一比例降至7/23(30%)。接受胃泌素瘤切除术的患者在随访影像学检查中均未出现复发性胃泌素瘤(最长随访时间:4年)。这项研究表明,95%的转移性胃泌素瘤在手术前即可被诊断出来,并且通过仔细的影像学检查和手术中的彻底探查相结合,30%的胃泌素瘤患者可能被治愈。